Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian®. Watson began shipping the product today. Kadian® is indicated to manage moderate to severe pain that continues around-the-clock and is expected to last for an extended period of time.
For the most recent twelve months ending September 30, 2011, Kadian® had sales of approximately $275 million, according to IMS Health data.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.